more_reports

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment

  ()
Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market.
Tags: Biotechnology / Pharmaceuticals

MindBio Therapeutics Positions Voice AI Kiosks for Growth in Workplace Safety Markets

  ()
MindBio Therapeutics advances prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, targeting high-growth opportunities in mining, aviation, and construction sectors amid expanding biotech and AI markets.
Tags: Life Sciences Tools & Diagnostics

MindBio Therapeutics Advances AI Voice Tech for Workplace Safety in Growing Biotech and AI Detector Markets

  ()
MindBio Therapeutics delivers first prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, positioning the company in high-growth sectors including mining, aviation, and construction, while analysts highlight significant upside potential.
Tags: Life Sciences Tools & Diagnostics

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors

  ()
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results

  ()
Oculis Holding AG (OCS:NASDAQ; OCS:XICE) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Launches Massive AI Safety Solution for Zero-Tolerance Industries

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) delivers first Edge AI intoxication detection kiosk prototypes for mining, aviation, and construction safety screening.
Tags: Life Sciences Tools & Diagnostics

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market

  ()
Grey Matters Health advances its Alzheimer's neuroimaging strategy with fresh financing and plans for the first U.S. brain-specific PET clinic, capitalizing on rising demand for early detection tools.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market

  ()
Explore how ORIC Pharmaceuticals is advancing its oncology pipeline with key catalysts ahead, amid rising global demand for innovative cancer treatments and strong analyst support.
Tags: Biotechnology / Pharmaceuticals

Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) closed the first CA$500,000 tranche of a financing that the company said will support its Alzheimer's disease program and planned U.S. brain-specific neuroimaging clinic.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth

  ()
ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) granted 34,800 stock options and 5,900 restricted stock units to new employees as analysts issue "Buy" ratings for the year ahead.
Tags: Biotechnology / Pharmaceuticals

From Healthcare IT Vendor to AI-Driven Holding Company

Contributed Opinion
  ()
Healthcare Triangle Inc.'s (HCTI:NASDAQ) Spanish AI acquisition delivers US$34M in revenue and a near-US$40M agentic AI run rate, while shares still trade at just 1x cash.
Tags: Healthcare Services

Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses

  ()
Rakovina Therapeutics (TSX.V: RKV) reported lower net losses, reduced administrative spending, debt restructuring, financing activity, and progress across its AI-driven oncology pipeline in Q1 2026.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%

  ()
Revolution Medicines Inc.'s (RVMD:NASDAQ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a "Buy" with targets up to US$263.
Tags: Biotechnology / Pharmaceuticals

US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug

  ()
Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60.
Tags: Biotechnology / Pharmaceuticals

New Alzheimer's Imaging Push Expands as Financing Terms Get Investor-Friendly

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) amended warrant terms tied to its CA$1 million private placement as it advances plans for a U.S. brain-specific neuroimaging clinic focused on Alzheimer's diagnostics.
Tags: Life Sciences Tools & Diagnostics

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Biopharma Company Reveals High-Impact SCI Recovery Gains

  ()
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs.
Tags: Biotechnology / Pharmaceuticals

200 Brain PET Scans, 162 Alzheimer's Drugs: A Diagnostic Push Takes Shape

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Cleantech Co. Wins PFAS Deal, Engineering Pact, Ships Clyra

Research Report
  ()
BioLargo (BLGO:OTCQX) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note
Tags: Life Sciences Tools & DiagnosticsCleantech

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans

  ()
Keros Therapeutics Inc. (KROS:NASDAQ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs.
Tags: Biotechnology / Pharmaceuticals

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles

Research Report
  ()
Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note.
Tags: Biotechnology / Pharmaceuticals